Physician profile
Alpana Java Pasricha
NPI 1801800222
$9,218.77
in general payments reported to CMS, 2019-2025
45 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,743 · 2020: $823 · 2021: $1,274 · 2022: $1,256 · 2023: $1,716 · 2024: $1,323 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,120 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,120.37 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,029.81 | 2019-2024 | Farxiga, Lokelma |
| Ani Pharmaceuticals, INC. | $668.59 | 2022-2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $623.08 | 2019-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $549.65 | 2019-2024 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $535.82 | 2023-2025 | |
| Travere Therapeutics, INC. | $533.66 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $512.58 | 2019-2025 | Jynarque |
| Amgen INC. | $438.55 | 2019-2025 | Tavneos, Krystexxa |
| Mallinckrodt Enterprises LLC | $338.90 | 2019 | |
| Daiichi Sankyo INC. | $321.70 | 2019-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $295.08 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $280.22 | 2021-2024 | Lupkynis |
| Teva Pharmaceuticals USA, INC. | $257.67 | 2019 | |
| Mdd US Operations, LLC | $254.75 | 2019 | |
| Horizon Therapeutics Plc | $251.55 | 2019-2023 | Krystexxa |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $250.02 | 2020-2025 | Terlivaz |
| Calliditas Therapeutics US INC. | $242.64 | 2022-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $217.40 | 2019-2025 | Ultomiris |
| Adamas Pharmaceuticals, INC. | $160.90 | 2019-2020 | |
| Teleflex LLC | $139.37 | 2025 | Deknatel |
| Biogen, INC. | $124.35 | 2021 | |
| Glaxosmithkline, LLC. | $116.60 | 2021-2023 | Benlysta |
| Fresenius USA Marketing, INC. | $115.89 | 2019-2025 | Velphoro, Velphoro |
| Nxstage Medical, INC. | $111.01 | 2023 | Nxstage System One |
| Acadia Pharmaceuticals INC | $106.03 | 2020 | |
| Ardelyx, INC. | $86.62 | 2024-2025 | Ibsrela |
| Kerecis Limited | $86.06 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.78 | 2024-2025 | Jardiance |
| Pharmacosmos Therapeutics INC. | $63.84 | 2022-2025 | Monoferric |
| Ultragenyx Pharmaceutical INC. | $55.94 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $50.77 | 2022 | |
| Lilly USA, LLC | $34.90 | 2023-2024 | Jardiance |
| Genentech USA, INC. | $34.22 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.35 | 2021 | |
| Veloxis Pharmaceuticals, INC. | $28.04 | 2020 | |
| Novo Nordisk INC | $26.59 | 2025 | Ozempic, Rybelsus |
| Kyowa Kirin, INC. | $26.07 | 2023 | Crysvita |
| Merck Sharp & Dohme LLC | $23.73 | 2025 | Zerbaxa, Prevymis |
| Cormedix INC. | $23.32 | 2024 | Defencath |
| Apellis Pharmaceuticals, INC. | $21.96 | 2025 | |
| Akebia Therapeutics INC | $20.86 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $19.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.65 | 2019 | |
| Medtronic, INC. | $15.22 | 2021 | |
| Amag Pharmaceuticals, INC. | $13.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alpana Pasricha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.